S&P ASX All Technology

US Dollar vs AUD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

VCNX Vaccinex Inc

1.41

0.00 (0.00%)

07 Feb 2025 - Closed

Delayed by 15 minutes

Form D - Notice of Exempt Offering of Securities

Vaccinex (NASDAQ:VCNX)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Vaccinex Charts.

Vaccinex (NASDAQ:VCNX)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Vaccinex Charts.

Vaccinex Inc News

Form 8-K - Current report
Wednesday 18 December 2024 (2 months ago) • Edgar (US Regulatory)

Vaccinex Announces Receipt of Delisting Notification from Nasdaq
Wednesday 18 December 2024 (2 months ago) • GlobeNewswire Inc.

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
Tuesday 19 November 2024 (3 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 19 November 2024 (3 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 19 November 2024 (3 months ago) • Edgar (US Regulatory)

Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Tuesday 19 November 2024 (3 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Friday 15 November 2024 (3 months ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Friday 15 November 2024 (3 months ago) • Edgar (US Regulatory)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Friday 15 November 2024 (3 months ago) • Edgar (US Regulatory)

Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
Friday 8 November 2024 (3 months ago) • GlobeNewswire Inc.

Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
Wednesday 6 November 2024 (3 months ago) • GlobeNewswire Inc.

Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain
Friday 1 November 2024 (3 months ago) • GlobeNewswire Inc.

More Vaccinex Inc News Articles

Lanterna Mortgage

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions